


CLAIMS

1. A compound of Formula I



Formula I;

wherein

R^1 is selected from the group consisting of $\text{C}_1\text{-C}_6$ alkyl, CF_3 , CH_2CF_3 , CF_2CHF_2 , $\text{C}_3\text{-C}_8$ cycloalkyl, wherein said $\text{C}_3\text{-C}_8$ cycloalkyl may be substituted with 1 or 2 substituents selected from the group consisting of $\text{C}_1\text{-C}_3$ alkyl, F, CHF_2 and CF_3 ; and

R^2 is H, $\text{C}_1\text{-C}_6$ alkyl or CF_3 ; or

R^1 and R^2 combine to form $\text{C}_3\text{-C}_5$ cycloalkyl optionally substituted with 1 or 2 F, CHF_2 or CF_3 ; and

R^3 is $\text{C}_1\text{-C}_3$ alkyl or $\text{CH}_2\text{O-C}_{1-3}$ alkyl, said $\text{C}_1\text{-C}_3$ alkyl or $\text{CH}_2\text{O-C}_{1-3}$ is alkyl substituted with $\text{C}\equiv\text{N}$, 3 F or $\text{C}_3\text{-C}_5$ cycloalkyl;

R^4 is selected from the group consisting of OCF_3 , or OCHF_2

or a pharmaceutically acceptable salt of any of these compounds.

2. The compound of according to claim 1, or a
pharmaceutically acceptable salt thereof, wherein R4
is OCF₃ or OCHF₂.
5
3. The compound according to any of the previous
claims, or a pharmaceutically acceptable salt
thereof, wherein R3 is selected from the group
10 consisting of CH₂-O-CF₃, CH₂-O- cyclopropyl, CH₂-C≡N
4. The compound according to any of the previous
claims, or a pharmaceutically acceptable salt
thereof, wherein R1 is C₃-C₄ cycloalkyl optionally
15 substituted with 1 or 2 C₁-C₃ alkyl, F, CHF₂ or CF₃.
5. The compound according to any of the previous
claims, or a pharmaceutically acceptable salt
thereof, wherein R1 and R2 combine to form
20 cyclobutyl optionally substituted with 1 or 2 F and
R4 is OCF₃ or OCHF₂.
6. The compound of claim 1, wherein the compound is
selected from the group consisting of:
25 (S)-N-((R)-2-cyclopropoxy-1-(3-(difluoromethoxy)
phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide;
(S)-N-((R)-1-(3-(difluoromethoxy)phenyl)-2-
(trifluoromethoxy)ethyl)-3-hydroxy-4,4-
dimethylpentanamide;

- (S)-N-((R)-1-(3-(trifluoromethoxy)phenyl)-2-(trifluoromethoxy)ethyl)-3-hydroxy-4,4-dimethylpentanamide;
- 5 (S)-N-((S)-2-cyano-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide;
- (S)-N-((S)-3-cyano-1-(3-(trifluoromethoxy)phenyl)propyl)-3-hydroxy-4,4-dimethylpentanamide;
- 10 (R)-N-(2-cyclopropoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide;
- (R)-N-(2-cyclopropoxy-1-(3-(difluoromethoxy)phenyl)ethyl)-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide;
- 15 (R)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(difluoromethoxy)phenyl)-2-(trifluoromethoxy)ethyl)acetamide; or
- (S)-N-(2-cyano-1-(3-(trifluoromethoxy)phenyl)ethyl)-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide
- 20 or a pharmaceutically acceptable salt of any of these compounds.

7. A compound selected from the group consisting of:
- 25 (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide;
- (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-
- 30 dimethylpentanamide;

- (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl) pentanamide;
(R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy) phenyl)ethyl)pentanamide;
5 (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-3-(1-(trifluoro-methyl)cyclopropyl)propanamide;
(S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-3-(1-
10 (trifluoro-methyl)cyclopropyl)propanamide;
(R)-N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxy-3-(1-(trifluoromethyl)cyclopropyl)propanamide;
(S)-N-((R)-2-(difluoromethoxy)-1-(3-
15 (trifluoromethoxy)phenyl) ethyl)-3-hydroxy-3-(1-(trifluoromethyl)cyclopropyl) propanamide;
(R)-3-(3,3-difluorocyclobutyl)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-
20 hydroxypropanamide;
(S)-3-(3,3-difluorocyclobutyl)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide
25 (R)-3-(3,3-difluorocyclobutyl)-N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide;
(S)-3-(3,3-difluorocyclobutyl)-N-((R)-2-(difluoromethoxy)-1-(3-
30 (trifluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide;

- (S)-3-(3,3-difluorocyclobutyl)-N-((S)-1-(3-(difluoromethoxy)phenyl)butyl)-3-hydroxypropanamide;
- 5 (R)-3-(3,3-difluorocyclobutyl)-N-((S)-1-(3-(difluoromethoxy)phenyl)butyl)-3-hydroxypropanamide;
- (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(1-ethylcyclopropyl)-3-hydroxypropanamide;
- 10 (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(1-ethylcyclopropyl)-3-hydroxypropanamide;
- (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)butyl)-3-hydroxy-4,4-dimethylpentanamide;
- 15 (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)-4,4-difluorobutyl)-3-hydroxy-4,4-dimethylpentanamide;
- (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)-3,3-difluoropropyl)-3-hydroxy-4,4-dimethylpentanamide;
- 20 (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide;
- (R)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)acetamide;
- 25 (R)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide;
- (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(difluoromethoxy)phenyl)butyl)acetamide;

- (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(difluoromethoxy)phenyl)-4,4-difluorobutyl)acetamide;
- 5 (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)propyl)acetamide;
- (S)-N-(3,3-difluoro-1-(3-(trifluoromethoxy)phenyl)propyl)-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide;
- 10 (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide;
- (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(1-fluorocyclopropyl)-3-hydroxybutanamide;
- 15 (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(1-fluorocyclopropyl)-3-hydroxybutanamide;
- (S)-N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-fluorocyclopropyl)-3-hydroxybutanamide;
- 20 (R)-N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-fluorocyclopropyl)-3-hydroxybutanamide;
- (R)-3-cyclopropyl-N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-
- 25 hydroxybutanamide;
- (S)-3-cyclopropyl-N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxybutanamide;

- (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-5,5,5-trifluoro-3-hydroxy-3-methylpentanamide;
- 5 (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-5,5,5-trifluoro-3-hydroxy-3-methylpentanamide;
- (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-3,5-dimethylhexanamide;
- 10 (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-3,5-dimethylhexanamide;
- (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-3,4-dimethylpentanamide;
- 15 (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-3,4-dimethylpentanamide;
- (S)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(3,3-dimethylcyclobutyl)-3-hydroxypropanamide;
- 20 (R)-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(3,3-dimethylcyclobutyl)-3-hydroxypropanamide;
- 25 (S)-3-cyclopentyl-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide;
- (R)-3-cyclopentyl-N-((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide;
- 30

- (R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide;
and (S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide
or a pharmaceutically acceptable salt of any of these compounds.
8. A pharmaceutical composition comprising a compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
9. A method of treating a patient in the need thereof suffering from epilepsy, bipolar disorder, migraine or schizophrenia comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof.
10. A method of treating a patient in the need thereof suffering from psychosis, mania, stress-related disorders, acute stress reactions, bipolar depression, major depressive disorder, anxiety, panic attacks, social phobia, sleep disturbances, ADHD, PTSD, OCD, impulsivity disorders, personality disorders, schizotypal disorder, aggression, chronic pain, neuropathy, autism spectrum disorders, Huntington's chorea, sclerosis, multiple sclerosis, Alzheimer's disease comprising

administering to the subject a therapeutically effective amount of a compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

5

11. Use of a compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, in therapy.

10

12. Use of a compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the treatment of epilepsy, bipolar disorder, migraine or schizophrenia.

15

13. Use of a compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the treatment of psychosis, mania, stress-related disorders, acute stress reactions, bipolar depression, major depressive disorder, anxiety, panic attacks, social phobia, sleep disturbances, ADHD, PTSD, OCD, impulsivity disorders, personality disorders, schizotypal disorder, aggression, chronic pain, neuropathy, autism spectrum disorders, Huntington's chorea, sclerosis, multiple sclerosis, Alzheimer's disease.

20

25

14. A compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating epilepsy, bipolar disorder, migraine or schizophrenia.

30

15. A compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating psychosis,

- mania, stress-related disorders, acute stress reactions, bipolar depression, major depressive disorder, anxiety, panic attacks, social phobia, sleep disturbances, ADHD, PTSD, OCD, impulsivity disorders, personality disorders, schizotypal disorder, aggression, chronic pain, neuropathy, autism spectrum disorders, Huntington's chorea, sclerosis, multiple sclerosis, Alzheimer's disease
- 5 disorders, personality disorders, schizotypal disorder, aggression, chronic pain, neuropathy, autism spectrum disorders, Huntington's chorea, sclerosis, multiple sclerosis, Alzheimer's disease
16. The compound or the pharmaceutical salt
- 10 thereof according to claims 1-7 or the pharmaceutical composition according to claim 16 for use in the treatment of epilepsy, epileptic syndromes, epileptic symptoms, treatment resistant or refractory epilepsy, or seizures.
- 15 17. The compound or the pharmaceutical salt thereof according to claims 1-7 or the pharmaceutical composition according to claim 16, for use in the treatment of Focal (partial) epilepsy with simple partial seizures, Focal
- 20 (partial) epilepsy with complex partial seizures, Generalized idiopathic epilepsy, Grand mal seizures, Status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and Benign Familial Neonatal Convulsions and other epileptic
- 25 syndromes (such as severe myoclonic epilepsy in infancy, epilepsy with continuous spike waves during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and Early myoclonic encephalopathy Ohtahara syndrome, or
- 30 seizures related to stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury,

stroke, brain cancers, autism spectrum disorders or metabolic disturbances (such as hyponatraemia).

18. The compound or the pharmaceutical salt
5 thereof according to claims 1-7 or the
pharmaceutical composition according to claim 16,
for use in the treatment epileptic symptoms as part
of neurogenerative disorders, such as Alzheimer's
disease, Lewy body disease, Huntington's disease
10 juvenile form, fronto-temporal lobar degeneration.
19. A method of treating a patient in the need
thereof suffering from epilepsy, epileptic
syndromes, epileptic symptoms, treatment resistant
15 or refractory epilepsy or seizures comprising
administering to the subject a therapeutically
effective amount of a compound of any of claims 1 to
7, or a pharmaceutically acceptable salt thereof.
20. A method of treating a patient in the need
20 thereof suffering from Focal (partial) epilepsy with
simple partial seizures, Focal (partial) epilepsy
with complex partial seizures, Generalized
idiopathic epilepsy, Grand mal seizures, Status
epilepticus, neonatal seizures, neonatal seizures,
25 KCNQ epileptic encephalopathy (KCNQ2EE) and Benign
Familial Neonatal Convulsions and other epileptic
syndromes (such as severe myoclonic epilepsy in
infancy, epilepsy with continuous spike waves during
slow-wave sleep, West syndrome, Lennox-Gastaut
30 syndrome, Dravet syndrome and Early myoclonic
encephalopathy Ohtahara syndrome, or seizures

- related to stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury, stroke, brain cancers, autism spectrum disorders or metabolic disturbances (such as hyponatraemia) or for use in the treatment of epileptic symptoms as part of neurogenerative disorders, such as Alzheimer's disease, Lewy body disease, Huntington's disease juvenile form, fronto-temporal lobar degeneration comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof.
21. Use of a compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the treatment of epilepsy, epileptic syndromes, epileptic symptoms, treatment resistant or refractory epilepsy, or seizures.
22. Use of a compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the treatment of for use in the treatment of Focal (partial) epilepsy with simple partial seizures, Focal (partial) epilepsy with complex partial seizures, Generalized idiopathic epilepsy, Grand mal seizures, Status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and Benign Familial Neonatal Convulsions and other epileptic syndromes (such as severe myoclonic epilepsy in infancy, epilepsy with continuous spike waves during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and Early myoclonic encephalopathy Ohtahara syndrome) , or seizures

related to stress, hormonal changes, drugs, alcohol, infection, or metabolic disturbances (such as hyponatraemia, or for use in the treatment epileptic symptoms as part of neurogenerative disorders, such as Alzheimer's disease, Lewy body disease, Huntington's disease juvenile form, fronto-temporal lobar degeneration.

23. A compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating epilepsy, epileptic syndromes, epileptic symptoms, treatment resistant or refractory epilepsy, or seizures.

24. A compound according to claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for Focal (partial) epilepsy with simple partial seizures, Focal (partial) epilepsy with complex partial seizures, Generalized idiopathic epilepsy, Grand mal seizures, Status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and Benign Familial Neonatal Convulsions and other epileptic syndromes (such as severe myoclonic epilepsy in infancy, epilepsy with continuous spike waves during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and Early myoclonic encephalopathy Ohtahara syndrome) or for use in the treatment epileptic symptoms as part of neurogenerative disorders, such as Alzheimer's disease, Lewy body disease, Huntington's disease juvenile form, fronto-temporal lobar degeneration.